CEO and senior executives in Egetis Therapeutics acquire shares
May 17, 2021
Stockholm, Sweden, May 17, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, Yilmaz Mahshid, incoming CFO, and Henrik Krook, Vice President Commercial Operations, have acquired shares in the company.
Nicklas Westerholm has bought 10,290 additional shares, Yilmaz Mahshid has bought 30,194 additional shares and Henrik Krook has bought 30,000 additional shares. Their respective total holdings now amount to 37,715, 156,000 and 73,955 shares in addition to warrants and employee stock options.